Publications by authors named "Yuefang Zhu"
Article Synopsis
- - FMX101 4% is a topical foam formulation of minocycline approved for treating moderate-to-severe acne vulgaris, and a study was conducted to evaluate its effectiveness and safety among Chinese patients.
- - In a phase 3 trial involving 372 subjects, results showed that FMX101 4% led to a significant reduction in inflammation lesion count (ILC) and noninflammatory lesion count (nILC), along with a higher treatment success rate compared to a control foam after 12 weeks.
- - The treatment was generally safe and well-tolerated, with mostly mild-to-moderate side effects and no serious adverse events linked to the treatment.
For the enhancement of the anticorrosion and antibacterial performance of the biomedical alloy Ti6Al4V, a novel Cu incorporated multilayer TaOceramic composite coating Cu-TaO/TaO/TaO-TiO/TiO/Ti (coating codeCu-MTaO) was developed by radio frequency (RF) and direct current (DC) reactive magnetron sputtering. Meanwhile, to better display the multilayer TaO coating mentioned above, a monolayer TaO ceramic coating was deposited onto the surface of Ti6Al4V alloy as a reference. The surface morphology, microstructure, phase constituents, and elemental states of the coating were evaluated by atomic force microscopy, scanning electron microscopy, X-ray diffraction, and X-ray photoelectron spectroscopy, respectively.
View Article and Find Full Text PDFBackgroud: The aim of the study was to evaluate the effect of early parenteral iron supplementation combined erythropoietin for prevention of anemia in preterm infants.
Methods: In total, 96 preterm infants were randomly assigned to 3 groups: a control group receiving standard parenteral nutrition (group 1: n = 31), an iron-supplemented group (group 2: IS, n = 33), and an iron-supplemented combined erythropoietin group (group 3: IS+EPO, n = 32). The primary objective was to assess hemoglobin (Hb) levels.